title: Increased tissue-plasminogen activator (t-PA) levels in patients under oral anticoagulant therapy.
abstract: The fibrinolytic system was investigated in 30 patients under oral anticoagulant therapy, and in 23 control patients not receiving oral anticoagulants. Patients under oral anticoagulant therapy had significantly higher tissue-plasminogen activator (t-PA) antigen levels than patients in the control group. Mean t-PA levels before venous occlusion were 18.4 ng/ml in the anticoagulated patients vs. 7.9 ng/ml in the control patients (p less than 0.001). After venous occlusion for 10 minutes, t-PA levels were 45.0 ng/ml in the anticoagulated patients and 24.2 ng/ml in the control patients (p less than 0.01). Plasminogen activator inhibitor (PAI) capacity was not significantly different in the two groups before venous occlusion (VO) but differed slightly (p less than 0.05) after VO. The net decrease in euglobulin lysis time (ELT) after venous occlusion (= ELT before VO - ELT after VO), indicating the relative potency of the fibrinolytic activity in blood, was also significantly higher in the anticoagulated patients (median 240 min vs. 125 min, p less than 0.001). These data indicate that oral anticoagulant therapy increases the fibrinolytic activity in blood, and thus may have an additional therapeutic effect in addition to anticoagulation.
authors.affiliation: Clinical Research Unit for Blood Coagulation and Thrombosis, Max-Planck-Gesellschaft, Giessen, Federal Republic of Germany.
authors.forename: J
authors.initials: J
authors.lastname: Grulich-Henn
authors.forename: K
authors.initials: K
authors.lastname: Loechelt
authors.forename: W
authors.initials: W
authors.lastname: Speiser
authors.forename: G
authors.initials: G
authors.lastname: Müller-Berghaus
mesh_terms: D015110:4-Hydroxycoumarins / Q000627:therapeutic use*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003250:Constriction; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010644:Phenprocoumon / Q000627:therapeutic use*; D010960:Plasminogen Activators / Q000037:antagonists & inhibitors; D015849:Plasminogen Inactivators; D010959:Tissue Plasminogen Activator / Q000097:blood*; D014680:Veins
chemical_list: D015110:4-Hydroxycoumarins; D015849:Plasminogen Inactivators; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D010644:Phenprocoumon